Amicus (FOLD) Flies to 52-Week High on $5-Billion BioMarin Merger [Yahoo! Finance]
Amicus Therapeutics, Inc. (FOLD)
Last amicus therapeutics, inc. earnings: 11/11 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.amicusrx.com/investor-relations
Company Research
Source: Yahoo! Finance
Amicus Therapeutics soared to a new 52-week high on Friday, jumping 30.21 percent to close at $14.18 apiece as investors gobbled up shares following announcements that it would merge with Biomarin Pharmaceutical for nearly $5 billion. At intra-day trading, the stock climbed to its highest price of $14.36 before trimming gains to finish the day just up by 30.21 percent at $14.18 apiece. Pixabay/Public domain This followed news on the same day that Amicus Therapeutics, Inc. (NASDAQ:FOLD) is set to be acquired by BioMarin in an all-cash transaction at a price of $14.50 apiece, representing a 33 percent premium over its closing price of $10.89 on Thursday, December 18. The agreement has already been approved by both firms' board of directors, but remains subject to other regulatory approvals, including shareholders. “Together with our partners in the rare disease community, we created a truly patient-centric biotech and successfully developed two transformative medicines for pe
Show less
Read more
Impact Snapshot
Event Time:
FOLD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FOLD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FOLD alerts
High impacting Amicus Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
FOLD
News
- Amicus Therapeutics (NASDAQ:FOLD) was downgraded by analysts at TD Cowen from a "buy" rating to a "hold" rating. They now have a $14.50 price target on the stock.MarketBeat
- Amicus Therapeutics (NASDAQ:FOLD) had its "neutral" rating reaffirmed by analysts at Citigroup Inc.. They now have a $14.50 price target on the stock, down previously from $17.00.MarketBeat
- Assessing Amicus Therapeutics Valuation After a 48.3% One Month Share Price Surge [Yahoo! Finance]Yahoo! Finance
- Amicus Therapeutics (NASDAQ:FOLD) had its "hold" rating reaffirmed by analysts at Needham & Company LLC.MarketBeat
- Shareholder Alert: The Ademi Firm investigates whether Amicus Therapeutics, Inc. is obtaining a Fair Price for its Public ShareholdersPR Newswire
FOLD
Earnings
- 11/4/25 - Beat
FOLD
Sec Filings
- 12/19/25 - Form 144
- 12/19/25 - Form DEFA14A
- 12/19/25 - Form 8-K
- FOLD's page on the SEC website